This site is intended for health professionals only

Published on 2 March 2011

Share this story:
Twitter
LinkedIn

Sativex® improves spasticity symptoms in half of MS patients

teaser

The cannabidiol Sativex® has shown further positive anti-spasticity results in patients with multiple sclerosis in a Phase III clinical trial.

The findings showed that about half of all people with moderate to severe spasticity due to multiple sclerosis (MS) who have responded inadequately to standard anti-spasticity therapy, experienced better control of spasticity with the addition of Sative oromucosal spray (delta-9-tetrahydrocannabinol [THC] and cannabidiol [CBD]), to their existing medication.

The primary efficacy endpoint was the change in a validated, 10 point (0-10) self-reported spasticity numerical rating scale (NRS) from the point of randomisation to the end of the treatment.

Sativex® was shown to provide significant improvement, compared to placebo, in the NRS spasticity score,  spasm frequency and sleep disturbance related to spasticity.

After a four-week, single-blind therapeutic trial period in 572 patients, Sativex® reduced the mean NRS score for spasticity by 3.01 points, from a baseline of 6.91 points.

The results, published online in the European Journal of Neurology Early View, showed that 48% of patients achieved a clinically meaningful improvement of ≥20% in spasticity severity during this initial period.

Of these responders, 241 proceeded into a 12-week, randomised, placebo-controlled trial phase.

At the end of the trial, Sative had reduced the mean spasticity 0-10 NRS score in responders by significantly more than placebo (estimated treatment difference 0.84 points; p=0.0002).

The number of patients achieving an improvement in spasticity NRS of ≥30% by the end of the trial was significantly greater in the Sativex group than the placebo group (74% vs. 51%; p=0.0003).

Professor John Zajicek, Honorary Consultant in Neurology, Derriford Hospital and Chair of Clinical Neurosciences at Peninsula College of Medicine and Dentistry, University of Plymouth said: “We have been aware for a long time that cannabinoid medicines can significantly improve spasticity, which is a common, complex symptom of MS, and now the results from this study prove the positive impact they can have on patients’ symptoms, and ultimately their lives.”

Bayer 2011



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn